Dec. 23 at 10:19 PM
Commercial-stage oncology focused bio valuation related data points for those with market caps north of
$1.5B
$SNDX is up sharply the last 5 months. In early August 2025, investors could buy SNDX for
$10/share. Since the ASH presentations, the market appears more confident longer-term revenue estimates are attainable. All the same, at
$22 a share SNDX still trades at meaningfully lower multiples of projected revenues than the others in this specific peer group.
$INCY could, in theory, buy SNDX for 4.0X FY29 revenue estimates consistent with peer M&A revenue multiples paid. Should INCY maintain a 4.2X FY29 revenue multiple the acquisition would, again in theory, be accretive to INCY shareholders.
$LEGN valuation continues to suffer in light of
$JNJ recent combo drug data that meaningfully outperformed Carvykti in R/R MM. It's been 2 weeks & we're unaware of any reduction in LEGN analyst projections (we could be wrong).
This is not investment advice (especially LEGN).
$XBI